These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24508038)

  • 1. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.
    Fransen MF; Cordfunke RA; Sluijter M; van Steenbergen MJ; Drijfhout JW; Ossendorp F; Hennink WE; Melief CJ
    Vaccine; 2014 Mar; 32(15):1654-60. PubMed ID: 24508038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
    Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
    Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
    Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
    Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.
    Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
    Biomaterials; 2015 Aug; 61():33-40. PubMed ID: 25993015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of agonistic anti-CD40 therapy in treatments for cancer.
    Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
    Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.
    Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ
    J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
    Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
    BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
    Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
    Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of an anti-CD40 agonist monoclonal antibody during immunizations enhances hybridoma generation.
    Rycyzyn MA; Staquet K; Fisher J; Bannish G; Bassiri A; Duchala C; Giles-Komar J
    Hybridoma (Larchmt); 2008 Feb; 27(1):25-30. PubMed ID: 18294073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
    Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
    J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles.
    Broos S; Sandin LC; Apel J; Tötterman TH; Akagi T; Akashi M; Borrebaeck CA; Ellmark P; Lindstedt M
    Biomaterials; 2012 Sep; 33(26):6230-9. PubMed ID: 22687756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.
    Jackaman C; Lew AM; Zhan Y; Allan JE; Koloska B; Graham PT; Robinson BW; Nelson DJ
    Int Immunol; 2008 Nov; 20(11):1467-79. PubMed ID: 18824504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
    Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
    Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
    Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis.
    Zhou Q; Gault RA; Kozel TR; Murphy WJ
    Infect Immun; 2006 Apr; 74(4):2161-8. PubMed ID: 16552046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
    Zippelius A; Schreiner J; Herzig P; Müller P
    Cancer Immunol Res; 2015 Mar; 3(3):236-44. PubMed ID: 25623164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
    Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
    J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.